Are payers waiting for lorundrostat's approval before making decisions on ASI products? What learnings are there from Baxfendy's payer and commercial performance?

Payer feedback is bullish on access for this innovation, particularly in the third and fourth-line position. While early for Baxfendy, there's recognition of the ASI class's innovation. Mineralys believes both agents will achieve equivalent payer positions, allowing lorundrostat's differentiated profile to be key. Baxfendy's rebate levels are consistent with expectations, and Medicare access relies on medical exceptions with favorable approval rates. “We haven't seen a lot of payer decisions yet, but we're firmly in a position to believe that both of these agents will be in an equivalent position that will give HCPs the ability to choose, and that's where our differentiated profile comes into play.”

Has the label and post-marketing conversation process begun with the FDA, and have expectations changed? When will pricing be locked in and communicated?

Label and post-approval commitment discussions typically start a couple of months before PDUFA (expected October/November). Dialogues with the agency have shown no surprises, and the data package is robust. Pricing analysis is ongoing, informed by Baxfendy's price, but the company does not anticipate sharing its price until approval and likely around launch. “I would not anticipate us sharing the price until approval and subsequently probably around launch.”

What aspects of lorundrostat's profile are resonating most with KOLs? What will be Dr. Terry Ferguson's priority list as the new CMO?

KOLs are most excited by lorundrostat's blood pressure reduction, which is considered best-in-class, combined with its safety and tolerability profile. The unique Advance-HTN data also resonates well. Dr. Ferguson's priorities will involve leveraging his expertise in late-stage development and medical affairs to amplify lorundrostat's message and relationships with KOLs, while Dr. Rodman continues to explore translational opportunities for aldosterone's role in cardiorenal metabolic disorders. “I just think really amplifies the message, the resonance, the relationships he has with KOLs. I think it's going to be a significant build for us as we continue to prepare lorundrostat for a successful commercial launch.”

MLYS

Mineralys Therapeutics (MLYS) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 11, 2026

Source: earnings call transcript

Executive summary

Mineralys Therapeutics Q2 FY26 — Strong Financial Position Ahead of PDUFA

Mineralys Therapeutics is in a strong financial position as it approaches the PDUFA date for lorundrostat, having secured substantial capital through an equity offering and term loan, alongside a strategic royalty repurchase. The company is actively building its commercial infrastructure and engaging with payers, while continuing to generate supportive clinical data for lorundrostat's potential best-in-class profile. Management expressed confidence in its launch readiness and the market opportunity for this new class of antihypertensive therapy.

Highlights

Ended Q2 FY26 with cash, cash equivalents and investments of $661.4 million, providing runway into 2028.
Successfully repurchased future royalty payments for lorundrostat for $200 million upfront, enhancing long-term value.
Secured a $500 million committed senior secured term loan facility, providing significant financial flexibility.
New Drug Application (NDA) for lorundrostat is under FDA review with a PDUFA date of December 22, 2026.
Presented positive post hoc analysis from Launch-HTN and proteomic data from Launch-HTN and Advance-HTN trials, reinforcing lorundrostat's potential.

Guidance & targets

Category	Target	Timeline	Confidence
Cash runway	Into 2028 high materiality	FY28	High
PDUFA date	December 22, 2026 high materiality	Q4 · FY26	High
Sales organization staffing	Staffed in advance of PDUFA date medium materiality	Q4 · FY26	High
Hypertension guidelines update	Sometime in 2027 medium materiality	CY27	Medium

Deals & partnerships

Tanabe Pharma Corporation Repurchase of potential future royalty payments related to lorundrostat $200 million upfront; up to $100 million once certain commercial milestones are met

Mineralys agreed to pay Tanabe $200 million upfront and up to $100 million in commercial milestones to repurchase future royalty payments for lorundrostat.

Pharmakon Advisors Committed senior secured term loan facility $500 million

Mineralys entered into a $500 million committed senior secured term loan facility with funds managed by Pharmakon Advisors.

What to watch in Q3 FY26

Lorundrostat PDUFA decision

December 22, 2026

Current NDA under FDA review

Target Approval decision

Why it matters

This is the primary regulatory milestone for lorundrostat, enabling commercial launch.

In the third quarter, we continue to build our commercial infrastructure as we approach our December 22 PDUFA date.

Find out whether MLYS delivers this. Inve re-checks your case every morning.

Q&A highlights

How is Mineralys finding the quality of sales candidates given competition from Baxfendy's launch, what attributes are they seeking, and when will the rest of the sales force be hired?

Management is excited about the high quality of candidates, attributing it to the innovative opportunity lorundrostat presents. They are looking for individuals aligned with company values and energized by the opportunity, not just cardiovascular experience. The goal is to have the full team in position ahead of the PDUFA date.

“I'm very comfortable with the quality of candidate and our ability to hit that target of having the full team in position ahead of the PDUFA.”

asked by Jin Law · answered by Jon Congleton

2 min read 5 chapters

Detailed narrative

Commercial Launch Readiness and Market Opportunity

Mineralys is systematically executing its commercial launch plan for lorundrostat, focusing on final readiness and execution ahead of the December 22 PDUFA date. The company has established relationships with hypertension specialists, engaged with payers covering the vast majority of US lives, and is developing a differentiated launch campaign.

Management believes lorundrostat's clinical profile aligns well with physician expectations for meaningful and durable blood pressure reductions, favorable tolerability, and fit within existing treatment algorithms, addressing the 20 million US adults with uncontrolled or resistant hypertension.

Strategic Financial Initiatives

During the quarter, Mineralys completed several strategic financial initiatives to enhance long-term value and financial flexibility. This included an agreement to repurchase future royalty payments for lorundrostat from Tanabe Pharma Corporation for $200 million upfront, with up to $100 million in commercial milestones.

Concurrently, the company completed a $150 million equity offering and secured a $500 million committed senior secured term loan facility with Pharmakon Advisors, positioning Mineralys to capture the long-term value of lorundrostat and fund operations into 2028.

Clinical Data Highlights and Future Development

The Transform-HTN open-label extension trial continues to generate long-term safety and efficacy data. Post hoc analysis from the pivotal Launch-HTN trial, presented at the European Society of Hypertension, showed comparable blood pressure reductions in CKD patients and a 52% placebo-adjusted reduction in urine albumin to creatinine ratio.

Late-breaking proteomic data from Launch-HTN and Advance-HTN, presented at ENDO 2026, demonstrated significant reductions in heart failure risk biomarkers. These findings strengthen the understanding of lorundrostat's potential benefits beyond blood pressure reduction, and the company continues to evaluate further clinical development.

Leadership Team Augmentation

Mineralys welcomed Dr. Terry Ferguson as Chief Medical Officer, bringing over 35 years of experience in cardiovascular medicine and clinical development. Dr. David Rodman, the previous CMO, will transition to a full-time strategic advisor role. This move is expected to augment the company's expertise in late-stage clinical activities and medical affairs, leveraging Dr.

Ferguson's relationships with KOLs and Dr. Rodman's deep knowledge of lorundrostat's development, particularly in exploring translational opportunities for cardiorenal metabolic disorders.

Payer and Competitive Landscape Insights

Payer engagement activities have been positive, with payers recognizing the unmet need in uncontrolled hypertension. While early, the launch of Baxfendy (baxdrostat) indicates enthusiasm for the Aldosterone Synthase Inhibitor (ASI) class. Mineralys anticipates that both ASI agents will achieve equivalent payer access, allowing lorundrostat's differentiated profile (best-in-class blood pressure reduction, favorable safety/tolerability, and unique Advance-HTN data) to drive adoption.

The company is finalizing its pricing strategy, aiming to maximize value while ensuring broad patient access.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.